McCormack joined GLSV in their Zug office earlier this year, where he has been active in assessing new investment opportunities and monitoring portfolio companies. He recently became chairman of the supervisory board of Intelligent Medical Implants following an investment which he led and closed for GLSV last month. Immediately prior to joining GLSV, he served as president and CEO of NeuroSystec, a California-based biotech company he co-founded which focuses on the use of implantable devices to deliver novel drug compounds for the treatment of neurological disorders.
Reithinger has been with GLSV in their Munich office since 2004 and has played a vital role in assessing new investment opportunities and monitoring portfolio companies. He represents GLSV on the boards of Neuraxo Biopharmaceuticals, Fibrex Medical, and Santaris Pharma. Before joining GLSV he was a director with 3i in their German healthcare practice and member of their European Sector Investment Committee.